Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New CEO Tobin, Three Approvals Signal Smoother Times For Boston Scientific

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific used the opportunity of its annual March meeting with analysts to announce the selection of James Tobin as the next CEO, a move aimed at allaying the financial community's ongoing concerns about the firm's management and direction.

You may also be interested in...

Medinol Suit Reveals Alleged Schism Among Boston Scientific Topsiders

Pressure is mounting for Boston Scientific to address the apparent rift between its senior-most executives, a division brought to light amidst a growing list of questions relating to the firm's relationship with Israeli stent partner Medinol.

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts